Watch: Atriva Therapeutics at BIO-Europe By Jim Cornall 1 minutemin December 19, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Leipzig Messe, Germany. Photo/Labiotech Newsletter Signup - Under Article / In Page"*" indicates required fieldsNameThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Germany by a team of scientists in viral research and industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.We spoke with founder and CEO, Rainer Lichtenberger at BIO-Europe, in Leipzig, Germany.Lichtenberger is set to retire in 2023, and his successor has been announced as Christian Pangratz.Are you interested in respiratory disease R&D? Download Inpart’s latest report, exploring the current research challenges, R&D trends, and breakthrough innovations in respiratory diseases. Read full report Explore other topics: Covid-19GermanyRespiratory disease ADVERTISEMENT